Skip to main content
Gencurix Inc. logo

Gencurix Inc. — Investor Relations & Filings

Ticker · 229000 ISIN · KR7229000005 KO Manufacturing
Open in API
Filings indexed 405 across all filing types
Latest filing 2023-10-25 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 229000

About Gencurix Inc.

https://www.gencurix.com/eng/

Gencurix Inc. is a molecular diagnostics company that develops and commercializes diagnostic solutions for precision medicine. The company's portfolio focuses primarily on oncology, offering prognostic, companion, and early detection tests. Key products include GenesWell BCT, a multigene prognostic test for early-stage breast cancer, and the GenesWell ddEGFR Mutation Test, a ddPCR-based companion diagnostic. Gencurix also utilizes its Droplex liquid biopsy platform for early cancer detection and develops diagnostic tests for infectious diseases. The company's core technologies include digital droplet PCR (ddPCR), real-time PCR, and liquid biopsy for analyzing circulating tumor cells (CTCs) and cell-free DNA (cfDNA).

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is specifically an amendment ('정정신고') to a previous filing. It details changes to stock option grants, including adjustments to exercise prices, number of shares, and beneficiary details due to corporate actions like capital increases and employee departures. This type of disclosure regarding stock-based compensation and capital structure changes falls under the category of regulatory filings for corporate actions.
2023-10-25 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of shares by Samsung Active Asset Management in the company 'Genexine' (젠큐릭스), crossing the 5% threshold. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided taxonomy.
2023-09-22 Korean
임시주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of an Extraordinary General Meeting (EGM) for the company Gencurix. It details the voting outcomes regarding the appointment of directors (board members). According to the filing definitions, official results from shareholder votes at any general meeting fall under the 'Declaration of Voting Results & Voting Rights Announcements' (DVA) category.
2023-09-13 Korean
[기재정정]전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) system regarding the acquisition of convertible bonds before maturity by the issuer (Gencurix). It specifically details the amendment of a previous filing ('정정신고') concerning the treatment of acquired bonds (cancellation vs. resale). Since this document relates to the company's capital structure and financing activities (specifically the repurchase and cancellation of debt instruments), it falls under the 'Capital/Financing Update' category.
2023-08-29 Korean
[기재정정]주주총회소집결의(임시주주총회)
AGM Information Classification · 98% confidence The document is a regulatory filing from Gencurix regarding the 'Resolution to Convene an Extraordinary General Meeting of Shareholders'. It details the agenda, including the appointment of directors, and provides specific meeting times and locations. This type of document is a formal notice to shareholders regarding an upcoming meeting and the matters to be voted upon, which falls under Proxy Solicitation & Information Statement (PSI).
2023-08-29 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a formal 'Notice of Extraordinary General Meeting' (주주총회소집공고) for Gencurix. It contains the meeting agenda, details on director nominations, and management information regarding the company's business status. While it includes management information, the primary purpose is to solicit shareholder attendance and votes for the upcoming meeting, which aligns with the definition of a Proxy Solicitation & Information Statement (PSI).
2023-08-29 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.